BSE filing, NSE: TEJNAKSH. Summary written from the filing by ALFA Finder's alert engine.
Tejnaksh Healthcare Ltd: key numbers
- Share price
- ₹12.89
- Market cap
- ₹26.18 Cr
- Revenue (annual)
- ₹10.79 Cr
- Net profit (annual)
- ₹1.23 Cr
- P/E (TTM)
- 21.2×Sector 51.1×
- Promoter holding
- 73.83%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Tejnaksh Healthcare Ltd
All →Tejnaksh Healthcare Business Update
Tejnaksh Healthcare announced publication of a multicentric validation study of its Pflow device in the Indian Journal of Urology. The filing is a scientific publication update with no financial value.
Tejnaksh Healthcare Management Change
Tejnaksh Healthcare shareholders approved the re-appointment of Mr. Suhas Vasantrao Thorat as an Independent Director for a second five-year term at the 18th Annual General Meeting.
Tejnaksh Healthcare Annual General Meeting
The company issued a notice for its Annual General Meeting scheduled for September 29, 2026, to consider financial statements, director appointments, and related party transaction approvals.
Tejnaksh Healthcare Annual Report
Tejnaksh Healthcare Limited has submitted its Annual Report for the financial year 2025-26. The filing includes audited standalone and consolidated financial statements along with governance reports.
Tejnaksh Healthcare Annual General Meeting
Tejnaksh Healthcare Ltd will hold its 19th Annual General Meeting on September 29, 2026. The meeting will be conducted via video conferencing to transact ordinary and special business.
Tejnaksh Healthcare Q1 FY27 Results: Net Profit ₹0.3 Cr, Up 50.0% YoY
Tejnaksh Healthcare Ltd reported revenue from operations of ₹2.7 Cr (+3.8% YoY) and net profit of ₹0.3 Cr (+50.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹0.3 Cr · +50.0% YoY
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.